About ALDX

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ALDX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 90.2 M 9.0207E+07 1,996 1996 0.0% 1.41177E-05 4 K 4159
UWM ProShares Ultra Russell2000 162.4 M 1.62362E+08 1,996 1996 0.0% 2.7403E-05 9 K 9274
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.4 B 2.04474E+10 3,545 3545 0.0% 0 38 K 37624
IWC iShares Microcap ETF 858.7 M 8.58676E+08 1,430 1430 0.04% 0.0004 324 K 324417
IWM iShares Russell 2000 ETF 41.2 B 4.12382E+10 1,985 1985 0.01% 0.0001 2.8 M 2778980
IWO iShares Russell 2000 Growth ETF 8.9 B 8.9462E+09 1,230 1230 0.01% 0.0001 1.2 M 1152640
IWV iShares Russell 3000 ETF 9.3 B 9.30666E+09 2,929 2929 0.0% 0 77 K 76753